Not admitted · Not a forecast
Rules 1.1.0 · as of 14 Sep 2026
Owen Scott Muir · Said 3 Oct 2023 · owen-0717
Quote
Not a forecast
“A reminder, this medical device is FDA approved, for use in children seven through 12, for the treatment of attention deficit hyperactivity disorder as a monotherapy. I suspect does quite a bit more than just that.”
173-word update of 2023-10-03 after three nights using the Monarch eTNS trigeminal nerve stimulator for the author's own ADHD. He notes the device is FDA approved as ADHD monotherapy for children 7 through 12 and suspects it does quite a bit more than that.
Descriptive, retrospective, or a statement of preference; no future state asserted.